Our wave is moving.
🟢 First patient enrolled in Wave II (Phase 2/3, LQTS Type 2).
🟢 FDA Fast Track Designation granted for THRV-1268. Initial data expected Q4 2026.
Full PR: https://bit.ly/4vGYlCw
#LQTS #RareDisease #FastTrack #Cardiology #Biotech
What an incredible week in Marrakech! Proud to sponsor the 7th Channelopathy Meeting (March 25–29, 2026), the first held in Africa. Dinesh Srinivasan presented our #SGK1 inhibition research for LQTS and beyond. 🧬❤️
🔗 https://channelopathy2026.org
#Channelopathy #IonChannels
Wave II is built around the people who make it possible. Every participant and caregiver has travel, meals & lodging covered—because living with Long QT Syndrome is already complex enough. 🌊
wavestudies.com/wave-2
#LongQTSyndrome #ClinicalTrials #RareDisease #LQTS2
🎙️ Thryv Therapeutics is participating in the Piper Sandler Virtual Cardio Day! Hear from our Chairman & CEO Paul Truex and CBO Matt Killeen, PhD on our LQTS and Heart Failure programs.
📅 April 2 · 9:00 – 9:25 a.m. ET · PSC clients only
#LQTS #HeartFailure #BiopharmaInvesting
🫀 Thryv Therapeutics will be at ACC.26 in New Orleans (March 28–30)! Our CMO Amy Sehnert, MD and CBO Matt Killeen, PhD are available to discuss our Long QT Syndrome and cardiometabolic disease programs.
Reach out to schedule a time: admin@thryvtrx.com
#ACC26 #LQTS #SGK1
We’re attending the Wells Fargo Virtual Private Biopharma Symposium (Apr 8). Sharing updates on our SGK1 inhibitor pipeline across arrhythmias, cardiometabolic disease & cardiomyopathies.
Connect: admin@thryvtrx.com
#Cardiology #PrecisionMedicine #SGK1 #ThryvTherapeutics
Excited to share two team updates at Thryv 🎉
👏 Justine has been promoted to Director, Finance.
👏 Sabindra’s title is now Associate Director, Non-Clinical Development.
Please join us in congratulating them both!
#TeamThryv #Leadership #ProfessionalGrowth #Biotech
🌍 ~59M people worldwide live with AF—and rising.
Last week, our VP of Clinical Research, Alex Brkovic, joined the AF-B-STEP kickoff in Amsterdam. Proud to support this global effort to better understand AF burden and its impact on stroke & heart failure.
Our AF-B-STEP Kick-Off Meeting last week was a great success, with valuable takeaways and a shared vision for the months ahead.
A big thank you to all participants👏- excited for the next steps and continued collaboration! 🤝
#AFBSTEP #AFib #AFBurden #HeartHealth #HealthInnovation #EUResearch #IHI
Every step forward begins with a moment 💚
Long QT Syndrome affects ~1 in 2,000 people, with no approved treatments today.
Wave II is now open for enrollment in the U.S.
👉 Click here for study details: www.wavestudies.com/wave-2
#LongQTSyndrome #LQTS2 #RareDisease #HeartHealth #ClinicalResearch
🚀 AF-B-STEP launches on 01 January 2026 🚀
🌐 afbstep.eu
A global collaboration redefining atrial fibrillation (AF) - from “yes” or “no” to what really matters. We analyse data from 100,000+ people to quantify the global burden of AF - aiming to improve diagnosis, treatment and outcomes. #HeartHealth
Nobody should miss a chance to live fully.
Through myQTwave, lived experiences help guide patient-centered care—so future generations of people with LQTS can thrive without limits.
It starts with you.
Together, we move forward. 💚
🌊 Learn more at www.myQTwave.com
We’re pleased to share positive Phase 1 results for THRV-1268, showing clear target engagement and QTcF shortening in obese participants. These data support SGK1 inhibition in cardiometabolic disease & HF. Phase 2a Aspire-HF planned for 2026.
🔗 www.newswire.ca/news-release...
Thryv Therapeutics is heading to SF for the 44th JPM Conference! We’ll be sharing updates on our SGK1 inhibitor programs and upcoming milestones.
Schedule a meeting: admin@thryvtrx.com
#JPM2026 #BiotechNews #LifeSciences #CardiacHealth #SGK1
We’re thrilled to welcome Matt Killeen, PhD, as CBO at Thryv!
With deep expertise in cardiovascular & genetic diseases, Matt will help drive our BD strategy and advance THRV-1268 toward Phase 2/3.
Link: loom.ly/4kCC3Oo
#SGK1 #Cardiology #Biotech #LQTS #HeartFailure #AFib
We’re highlighting new updates on myQTwave, our remote study for people with LQT2/LQT3. Thank you to advocate Tiffany Stayer for her perspective.
Full announcement: loom.ly/9yELMXU
#LQTS #myQTwave #DigitalHealth
We’re excited to welcome Amy Rudolph, PhD, to Thryv Therapeutics’ Board! Her medical affairs and cardiovascular drug development expertise will help advance THRV-1268 and our SGK1 platform.
Read more: www.newswire.ca/news-release...
#SGK1 #Cardiology #Biotech #LQTS #HeartFailure #AFib
Exciting updates from #AHA25! 🎉
Our CMO, Dr. Amy Sehnert, and co-founder, Dr. Saumya Das, presented 3 posters on SGK1 inhibition in heart failure.
Our new preprint, “A novel SGK1 inhibitor improves cardiac structure & function”, is now live: researchsquare.com/article/rs-7...
#HeartFailure #SGK1
Thryv Therapeutics will present 3 moderated e-posters at #AHA25 on THRV-1268, part of our SGK1 inhibitor portfolio targeting heart failure & cardiac remodeling.
📍 Nov 8–10 | New Orleans
Read more: loom.ly/gXgaJEQ
#CardioResearch #HeartFailure
Thryv Therapeutics will join the Wells Fargo, Stifel, Jefferies & RBC investor conferences to share our vision for transforming cardiovascular care through SGK1 inhibition.
👉 Read more: loom.ly/tUk3fWY
#ThryvTherapeutics #SGK1 #Biotech #LQTS #AFib #HeartFailure
With FDA IND clearance and investor backing, Thryv is advancing THRV-1268, our lead SGK1 inhibitor, into Phase 2/3 for Long QT Syndrome—bringing us closer to the first approved therapy for people with LQTS.
👉 loom.ly/tZj96M8
#SGK1 #LQTS #Biotech
📣 We’re headed to #ESCCongress! Excited to share compelling new preclinical results on our lead SGK1 inhibitor, THRV-1268.
🗓️ Aug 30 – Heart Failure | Dr. Saumya Das
🗓️ Aug 31 – LQTS | Dr. Simona Casini
Details 👉 loom.ly/LPHc97A
#SGK1 #Cardiology
🔬 Behind the scenes in the lab!
Our team is advancing SGK1 inhibition to help treat LQTS, AFib & heart failure. From bench to breakthrough.
#SGK1 #CardiacResearch #TeamThryv
🌍 On #ClinicalTrialsDay, we celebrate the power of research—especially in rare diseases, where each trial brings hope. Thank you to the patients, researchers & HCPs driving progress.
At Thryv, we’re proud to advance treatments for LQTS, heart failure & AF. 💚
#ResearchMatters
Thryv to share latest clinical results of SGK1 inhibition in patients with LQTS at RBC (May 20–21) & Jefferies (June 3–5). Learn more about our SGK1 platform for LQTS, HF & AFib.
📄 Press release: loom.ly/sIJ8l0c
📩 admin@thryvtrx.com
#ThryvTherapeutics #SGK1 #LQTS
👩⚕️ Nurses are the heart of healthcare. On this #InternationalNursesDay, we recognize their power to shape stronger health systems.
At Thryv, we’re proud to work with nurses advancing cardiovascular care and clinical research. 💚
#ThankYouNurses #NursesTransformCare
May is #StrokeAwarenessMonth. Stroke is the most serious complication of #AFib, increasing risk 5x. At Thryv, we’re targeting SGK1 to address the biology behind AFib. Know the signs:
👤 Face drooping
💪 Arm weakness
🗣️ Speech trouble
📞 Time to call 911. #FAST #HeartHealth
📣 Join us Sunday at #HRS2025!
🗓️ Apr 27 | 8–9 AM PT
📍 Hub 4 – Sails Pavilion, SDCC
👨⚕️ Dr. Philip Sager presents new clinical data from Wave I, Part 2: SGK-1 Inhibition with LQT-1213 Significantly Reduces QTcF in Patients with Congenital Long QT Syndrome
#LQTS #SGK1
We’re proud to have a team of innovators from both sides of the border advancing treatments for Long QT Syndrome, heart failure & AFib.
With the FDA, we're united in bringing new options to those living with cardiovascular disease. 💚
#TeamThryv #LQTS #SGK1 #Biotech
Thryv Therapeutics is excited to join the 2025 Piper Sandler Virtual Cardio Day on April 1! Our leadership team will sit for a fireside chat at 11:30 a.m. ET, sharing insights on SGK1 inhibition for LQTS, HF & AFib.
📢 Read more: thryvtrx.com/news/piper-s...
#PiperSandler #SGK1 #BioTech
